[Featured Stock] Geninus, Personalized Cancer Vaccine with Medical AI Up... Samsung Genome Research Institute Spin-off Company

Geninus is showing strong performance. As the time to prove the value of its self-developed platform as an artificial intelligence (AI) drug development company approaches, buying orders are continuing.

At 10:01 a.m. on the 21st, Geninus was trading at 3,945 won, up 23.67% from the previous day.

Geninus is a company spun off from Samsung Genome Research Institute at Samsung Medical Center in 2018. Its main business areas are single-cell analysis (Cellinus), NGS cancer diagnostics (tissue biopsy · liquid biopsy), and DTC health management services.

Songhyeop Han, a researcher at Daishin Securities, explained, "They have secured top-tier cancer genome information data in Korea," adding, "They show strengths in the bioinformatics field that provides meaning to the analyzed sequence data using this database."

He continued, "Single-cell analysis can serve as a kind of ‘biomarker’ that selects patients with good drug efficacy for new drug development," and added, "They actually confirmed changes in the distribution of CD8 T cell types according to drug responsiveness for U.S. clients." Furthermore, he analyzed, "Geninus’s single-cell analysis capabilities are among the top worldwide standards," and "It is judged that overseas expansion is also possible."

Geninus is building an AI drug development platform based on single-cell analysis technology. Geninus combined single-cell analysis and bioinformatics algorithms to establish the tumor neoantigen prediction platform ‘VACINUS.’

Among the neoantigen candidates selected by Geninus’s self-developed neoantigen derivation algorithm VacPipe, three selected candidates were confirmed to have synergy with PD-1 immune checkpoint inhibitors in terms of anticancer efficacy. The mouse model in the treatment group showed a significant increase in survival rate compared to the control group, and tumor growth was suppressed by more than 50%.

The related industry expects the value of the AI drug development platform to be confirmed when the new drug candidates discovered through the platform enter clinical trials and when clinical data are disclosed after clinical entry. Geninus’s personalized anticancer vaccine is expected to enter domestic Phase 1 clinical trials as early as next year. A researcher predicted, "After meeting with the Korea Food and Drug Administration, it is expected to receive IND approval for domestic Phase 1 trials in the first half of next year."